TrialCancer science2026

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.

Tetsuya Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.